Medrx Co.,Ltd. Logo

Medrx Co.,Ltd.

Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.

4586 | T

Overview

Corporate Details

ISIN(s):
JP3921220004
LEI:
Country:
Japan
Address:
東かがわ市西山431番地7
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Medrx Co., Ltd., established in 2002, is a pharmaceutical company focused on drug formulation development. The company specializes in creating new dosage forms and value-added medicines, with a core technological expertise in transdermal absorption and drug delivery systems. Medrx conducts research and development to create innovative pharmaceutical candidates, which it then licenses to other companies for final clinical trials, production, and commercialization. The company's primary goal is to improve global health and patient quality of life by developing medications that offer alternatives to conventional oral administration, thereby improving patient adherence and therapeutic effectiveness.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:33
Interim Report
確認書
Japanese 8.9 KB
2025-08-08 08:31
Interim Report
半期報告書-第24期(2025/01/01-2025/12/31)
Japanese 425.8 KB
2025-06-13 08:31
Share Issue/Capital Change
臨時報告書
Japanese 39.1 KB
2025-03-31 08:33
Governance Information
内部統制報告書-第23期(2024/01/01-2024/12/31)
Japanese 23.9 KB
2025-03-31 08:32
Registration Form
確認書
Japanese 8.7 KB
2025-03-31 08:32
Post-Annual General Meeting Information
臨時報告書
Japanese 25.0 KB
2025-03-31 08:32
Registration Form
訂正有価証券届出書(組込方式)
Japanese 271.6 KB
2025-03-31 08:31
Registration Form
有価証券報告書-第23期(2024/01/01-2024/12/31)
Japanese 1.4 MB
2025-03-28 07:31
Registration Form
訂正有価証券届出書(組込方式)
Japanese 268.0 KB
2025-03-25 07:31
Registration Form
有価証券届出書(組込方式)
Japanese 409.6 KB
2024-08-09 08:01
Interim Report
確認書
Japanese 8.8 KB
2024-08-09 08:00
Interim Report
半期報告書-第23期(2024/01/01-2024/12/31)
Japanese 345.0 KB
2024-05-17 08:01
Share Issue/Capital Change
臨時報告書
Japanese 39.2 KB
2024-05-10 08:02
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-05-10 08:01
Quarterly Report
四半期報告書-第23期第1四半期(2024/01/01-2024/03/31)
Japanese 408.3 KB

Automate Your Workflow. Get a real-time feed of all Medrx Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medrx Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medrx Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

HireQuest, Inc. Logo
A franchisor of staffing solutions offering temporary labor and skilled placement to diverse industries.
United States of America
HQI
H.I.S. Co., Ltd. Logo
A major Japanese travel agency providing global tour packages, lodging, and transport.
Japan
9603
Hit Co., Ltd. Logo
Specialized OOH advertising firm providing digital & static billboards in high-visibility areas.
Japan
378A
HLB Therapeutics Co.,Ltd. Logo
Develops innovative drugs for rare eye diseases and brain tumors, with vaccine logistics.
South Korea
115450
HONYAKU Center Inc. Logo
Provides industrial translation and interpreting for patent, legal, and corporate clients.
Japan
2483
A holding company for advanced materials, AI/data solutions, mobility, and global logistics.
South Korea
487570
Human Metabolome Technologies, Inc. Logo
A leader in metabolomics, providing CE-MS analysis to support R&D in biotech, pharma, and food.
Japan
6090
Hybrigenics SA Logo
R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.
France
ALHYG
Korean CRO offering end-to-end clinical trial services for pharma & bio ventures.
South Korea
187660
HYUNDAI BIOSCIENCE CO., LTD. Logo
Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.
South Korea
048410

Talk to a Data Expert

Have a question? We'll get back to you promptly.